# Professor 2: Advisor, computer science (strictness=medium)

## Scores
A: 8.5
B: 8.0
C: 8.0
D: 8.5
E: 8.0
F: 8.0
G: 7.0
H: 8.0
I: 9.0
J: 8.0
total: 80.0/100

## Rationale (≤3 sentences each item)
A: The problem statement is concrete and appropriately scoped: region-level, single-position hotspot prioritization for RNA-virus surface glycoproteins, not universal mutation prediction. The dissertation clearly separates standardized benchmarking, pathogen-dependent information utility, and external escape enrichment as distinct aims. The only deduction is that the practical target sometimes oscillates between benchmark infrastructure, wet-lab triage, and cold-start selection, requiring repeated ledgers to stabilize the claim.

B: The related-work coverage is broad and current, spanning hotspot detection, cancer analogues, DMS/VEP benchmarks, protein language models, surveillance platforms, and algorithm selection. The comparison to ProteinGym, EVEREST, ViroGym, EVEscape, Nextstrain, PANGO, HyPhy, and MutClust is useful and generally fair. Some sections are over-dense and occasionally lean on very recent preprints as positioning anchors, so the literature synthesis is strong but not maximally elegant.

C: The methodology is substantial: 20 scoring formulas, 39 detector variants, 11 pathogens, three-layer ground truth, MCC/hotspot-score metrics, ANOVA, Friedman, LOPO, bootstrap, vaccine-escape audit, and multiple negative adaptive-selection checks. The major strength is explicit separation of Layer A/B/C roles and extensive robustness framing. The main methodological limitation is label heterogeneity and single-team curation of Layer A, which affects the central MCC target even though it is candidly disclosed.

D: The experimental scale is strong for a dissertation: 8,580 main evaluations plus Stage 3 feature analyses, escape audits, temporal backtests, Wave 4/5 sensitivity checks, and adaptive-weighting failures. The pathogen breadth is meaningful across RNA-virus surface glycoproteins. The deduction is that the effective independent sample size for cross-pathogen generalization remains 11 pathogens, with external escape validation available for only 3 of 11.

E: The interpretation is disciplined and usually avoids overclaiming: LOPO 0/11 is treated as null-consistent, H3N2 is self-consistency, SARS-CoV-2 is exploratory, and HIV-1 is the primary external anchor. The thesis correctly converts failed adaptive-selection attempts into a bounded non-deployability result. Still, some positive language around practical recipes and search-space reduction is stronger than the forward-time evidence can fully support, even with the caveats.

F: The contribution is original in combining region-level hotspot benchmarking, multi-information-source comparison, pathogen-by-information interaction quantification, and escape-enrichment auditing. The scoring-by-pathogen interaction and evidence ledger make the work more than a method bake-off. Novelty is somewhat bounded by dependence on existing scoring families and by the fact that the deployable adaptive selector is explicitly not achieved.

G: Practical value is real but limited: narrowing roughly 1,000 positions to 10--50 candidates with HIV-1 7.19x enrichment is useful for retrospective wet-lab triage. However, the prospective backtests are weak overall, callability remains 0/12, and adaptive methods fail at the current panel size. Therefore the value is better described as a benchmark and triage aid than as an operational detector.

H: The writing is clear at the claim-boundary level, with repeated ledgers that help examiners see what is proved, bounded, negative, or future work. Tables and captions are unusually informative. The deduction is for density and redundancy: many caveats are correct but repeated so often that the central narrative becomes harder to read than necessary.

I: Limitations awareness is excellent. The dissertation explicitly addresses Layer A heterogeneity, circularity, small-cluster inference, winner's curse, prospective validation gaps, label-provenance non-equivalence, dual-use risk, and independent reproduction. This is one of the strongest aspects of the manuscript.

J: Overall maturity is good: the project has a coherent benchmark artifact, reproducibility/provenance claims, robust statistical checks, and a balanced conclusion. It is not yet excellent because the central empirical evidence remains retrospective, externally validated on a convenience subset, and dependent on a small pathogen panel with heterogeneous labels. As an advisor, I would consider it defensible with targeted tightening rather than requiring a fundamental redesign.

## Critical concerns (if any item < 6)
None.

## Strongest single deduction
G, practical value: the work demonstrates retrospective triage and HIV-1 escape enrichment, but prospective deployment is not supported; fix by expanding to 20--30+ curated pathogens with time-forward labels and a predeclared callability gate.

RESULT_PROF_V7_02: total=80.0/100 min_item=7.0(G) max_item=9.0(I)
